Compare Enveric Biosciences Inc (ENVB) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Li Auto Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Li Auto Inc trades at $11.4 (market cap $10.71B). The key difference: Li Auto Inc is far larger — about 1575× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 1,781,143). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Li Auto Inc for 101 Days on average.
| ENVB | LI | |
|---|---|---|
Market Cap | $6.80M | $10.71B |
Volume | 64,867 | 1,781,143 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $23.61 |
52-Week Low | $1.27 | $10.69 |
Typical Hold Time | 14 Days | 101 Days |
Enterprise Value | -$1.49M | $139.58M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Li Auto (LI) trades at $10.99, near its 52-week low, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. Revenue declined to $112.31B in 2025, with a net income margin of 1%, while cash flow from operations turned negative. The company faces intense competition in China's EV market, though new model launches like the Li i9 aim to revive growth.
The stock presents a high-risk opportunity, with a consensus price target of $15.18 implying upside, but investors must weigh analyst caution (43.75% buy rating) against execution risks and ongoing cash burn. Near-term performance hinges on delivery recovery and margin improvement amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
